SCHEMBL8337307

SCHEMBL8337307

CC(O)C(N1CCN(c2ccc(F)cc2)CC1)n1c(-c2ccccc2)nc2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
KDM4E B2RXH2 2/20 0.43
LMNA P02545 2/20 0.43
GRIA1 P42261 1/20 0.43
CACNG8 Q8WXS5 1/20 0.43
CACNG2 Q9Y698 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
RAD52 P43351 1/20 0.43
KDM1A O60341 1/20 0.41
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
TSHR P16473 1/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39
TP53 P04637 2/20 0.39
ALPG P10696 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8333978 0.88 RAD52 (0.42) MAPTKDM4ELMNAGRIA1CACNG8
SCHEMBL6844237 0.75 TSHR (0.56) MAPTKDM4ELMNASMN1; SMN2TSHR
SCHEMBL27952100 0.71 ALDH1A1 (0.69) MAPTKDM4ELMNAGRIA1CACNG8
SCHEMBL4305298 0.68 GRM2 (0.58) MAPTKDM4ELMNASMN1; SMN2GAA
SCHEMBL2607467 0.68 ALDH1A1 (0.72) MAPTKDM4ELMNAL3MBTL1KMT2A
SCHEMBL6839523 0.68 MAPT (0.57) MAPTKDM4ELMNAKMT2AMEN1
Hydrochloric Acid SCHEMBL8021989 0.66 KDM4E (0.48) MAPTKDM4ELMNAKMT2AMEN1
SCHEMBL9694043 0.65 HSD17B10 (0.52) MAPTKDM4ELMNAL3MBTL1KMT2A
SCHEMBL13033400 0.64 SMO (0.46) KDM4ERAB9ANPC1SMN1; SMN2
SCHEMBL8027446 0.64 KDM4E (0.61) MAPTKDM4ELMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5889010-A PSYCHOLOGICAL DISORDERS; UROGENITAL DISORDERS; COGNITION ACTIVATORS; NERVOUS SYSTEM DISORDERS; VISION DEFECTS; CONGESTIVE HEART FAILURE; DRUG ABRUSE; PARKINSON'S DISEASE;ANTIINFLAMMATORY AGENTS; ANTIALLERGENS PFIZER INC. (US) 1999-03-30 US disclosed